Which triptan is preferred for treating migraine in pregnant patients?

Preferred Triptan in Pregnancy

Sumatriptan is the preferred triptan for treating migraine in pregnant patients, as it has the most extensive safety data demonstrating no increased risk of major birth defects or adverse pregnancy outcomes compared to the general population.

Evidence-Based Rationale

The most recent 2025 American College of Physicians guideline explicitly addresses pregnancy considerations, stating that in people who are pregnant or breastfeeding, clinicians should discuss adverse effects of pharmacologic treatments during pregnancy and lactation 1. Importantly, the guideline specifically notes that CGRP antagonists, ergot alkaloids, and ditans should only be used in "nonpregnant outpatient adults," effectively excluding these newer agents from use in pregnancy 1.

Why Sumatriptan Specifically

Among all triptans, sumatriptan has the most robust pregnancy safety data:

• Largest evidence base: Multiple prospective observational studies and pregnancy registries have tracked sumatriptan exposure with no increased risk of major birth defects (OR 0.84; 95% CI 0.4-1.9), spontaneous abortions (OR 1.20; 95% CI 0.9-1.7), preterm delivery (OR 1.01; 95% CI 0.7-1.5), or preeclampsia (OR 1.33; 95% CI 0.7-2.5) 2

• First trimester safety confirmed: The critical period for teratogenesis shows no signal for increased malformations above the baseline 3-5% population rate 3, 4

• Expert consensus: Multiple reviews consistently identify sumatriptan as "an acceptable treatment option" and the "preferred drug" when triptans are needed during pregnancy 5, 6

Clinical Algorithm for Pregnant Patients

First-Line Approach

1. Start with acetaminophen (paracetamol) - safest option throughout pregnancy 5
2. Consider NSAIDs (like ibuprofen) only in second trimester if acetaminophen fails - avoid in first and third trimesters due to specific risks 5

When to Use Sumatriptan

1. If acetaminophen insufficient: Use sumatriptan for sporadic treatment of moderate-to-severe attacks 5
2. Route considerations: Both oral and subcutaneous formulations have safety data, though subcutaneous has been more extensively studied 7, 3

Important Caveats

• Other triptans lack data: While naratriptan and rizatriptan have limited reassuring data, they cannot be recommended over sumatriptan due to insufficient evidence 3, 6

• Detailed ultrasound recommended: If first-trimester exposure occurs to less well-studied triptans, offer detailed fetal ultrasound 2

• Avoid newer agents entirely: Do not use gepants (rimegepant, ubrogepant, zavegepant), ditans (lasmiditan), or ergot alkaloids in pregnancy 1

• Combination therapy: The 2025 VA/DoD guideline recommends sumatriptan combined with naproxen for non-pregnant patients 7, but in pregnancy, avoid this combination in first and third trimesters due to NSAID risks

Breastfeeding Considerations

Sumatriptan is also the preferred triptan during breastfeeding, as minimal amounts are excreted into breast milk, insufficient to cause adverse effects in nursing infants 6.